MEDIUM confidence
Researched 2026-07-22 22:43 · profile: researcher
Programme Thesis
The DoW Amyotrophic Lateral Sclerosis Research Program Therapeutic Idea Award funds early-stage, high-risk/high-reward research concepts that could lead to new treatments or interventions for ALS. It exists to accelerate innovative therapeutic approaches that are not yet mature enough for traditional funding, with a focus on military relevance and translational potential.
Selection Criteria
1. Innovation and impact of the proposed therapeutic idea (primary). 2. Scientific rationale and preliminary data supporting the hypothesis. 3. Feasibility of the research plan within the award period and budget. 4. Qualifications and experience of the Principal Investigator and team. 5. Relevance to ALS and potential for clinical translation. 6. Budget justification and appropriateness. 7. For the General Track: no specific military connection required, but broader DoD mission alignment is valued.
Past Winners / Cohort Profiles
Past winners typically include early-career investigators (postdocs, junior faculty) and established researchers proposing novel mechanisms or drug repurposing for ALS. Examples from similar DoD/CDMRP programs often feature single-PI projects with strong preliminary data, clear milestones, and a focus on target identification, biomarker development, or therapeutic screening. No specific named winners were found on the page.
Ideal Candidate Fingerprint
The platonic ideal applicant is an early-career researcher with a bold, testable therapeutic hypothesis for ALS, supported by strong preliminary data (even if from other disease models), and a clear plan to generate proof-of-concept results within 1-2 years. They have a track record of independent work, relevant technical skills, and a compelling narrative linking their idea to ALS pathology or treatment.
Recommended Framing
Eniola should frame their CCT model as a novel computational framework for identifying drug combinations that prevent aberrant synaptic consolidation—a process implicated in ALS neurodegeneration. They can argue that the same super-additive pharmacology principles validated in addiction could be repurposed to target TDP-43 aggregation or glutamate excitotoxicity, leveraging their Bayesian modeling and ODE/RK45 validation as strong preliminary data. Emphasize the independent, pre-registered, and peer-reviewed nature of their work, plus endorsements from Berridge and Gershman, to offset the lack of direct ALS experience.
Watch Out
No direct ALS research experience or publications; the CCT model is currently focused on addiction, not neurodegeneration. The applicant is not affiliated with a US institution (Nigerian independent researcher), which may raise eligibility or administrative concerns for a DoD grant. The award amount is unspecified but likely modest ($50K-$150K); the applicant's budget and timeline must be tightly scoped. No preliminary data in ALS models.